Announced
Synopsis
Agilent Technologies, an analytical and clinical laboratory technologies firm, agreed to acquire BIOVECTRA, a global biotech and pharmaceutical company, for $925m. “BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours. BIOVECTRA has dedicated nearly 55 years to the relentless pursuit of helping our customers solve complex problems that improve patients’ lives. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers,” Oliver Technow, BIOVECTRA CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.